특발성 저신장증 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the idiopathic short stature market size is expected to grow from USD 1.73 billion in 2025 to USD 1.87 billion in 2026 and is forecast to reach USD 2.80 billion by 2031 at 8.34% CAGR over 2026-2031.

This report is Segmented by Therapy Type (Branded RhGH, Biosimilar RhGH, and More), Age Group (Pre-Pubertal Children, and More), Route of Administration (Daily Subcutaneous Injection, and More), End User (Hospitals, Specialty Endocrine Clinics, Home-Care Settings), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Idiopathic Short Stature Market Trends and Insights

Rising Prevalence of ISS Diagnosis

Next-generation sequencing has reduced the cost and turnaround time for genetic evaluations, enabling clinicians to exclude monogenic causes such as SHOX deficiency and reclassify children into the idiopathic short stature market treatment pool. An October 2025 guideline recommends multiplex ligation-dependent probe amplification for all children below -2.5 standard deviations, which standardizes referrals. In Abu Dhabi, idiopathic short stature accounted for 34.8% of all rhGH prescriptions from 2011 to 2022, surpassing growth hormone deficiency. Although the diagnostic yield of sequencing remains 14.9%, the significant increase in screened children is driving demand. As more hospitals implement electronic growth charts, deviations prompt earlier specialist referrals, increasing volume in North America and the Gulf.

Growing Adoption of rhGH Biosimilars

Price-competitive biosimilars are transforming the idiopathic short stature market in China and India, where domestic manufacturers obtained National Reimbursement Drug List coverage in January 2026, reducing annual therapy costs by more than 50%. Intas Pharmaceuticals' fermentation-to-fill pipeline provides a cost advantage once Indian state payers finalize reimbursement rules. In Latin America, mandatory coverage in Argentina is hindered by administrative bottlenecks that disrupt supply and negatively impact clinical outcomes. Europe and North America lag behind as physicians remain loyal to originator brands and regulatory requirements for immunogenicity data extend approval timelines.

Stringent Regulatory Scrutiny & High Therapy Cost

The EMA's 2007 refusal to approve idiopathic short stature contrasts with FDA acceptance and establishes a two-tier access structure, as European payers cite ethical concerns when rejecting claims. U.S. annual therapy costs of USD 20,000-50,000 push insurers toward strict prior-authorization, while pediatric endocrine societies advise caution, reinforcing payer denials. Long-acting analogs face additional safety checks because continuous GH exposure increased edema rates in trials. Argentine private insurers systematically defer coverage for premium analogs despite local approval, framing high cost as the primary barrier.

Other drivers and restraints analyzed in the detailed report include:

1. Expanded Insurance Reimbursement
2. Long-Acting GH Formulations Pipeline
3. Low Awareness / Delayed Diagnosis in Low-Income Countries

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

In 2025, branded rhGH held a 62.20% market share. However, long-acting analogs are set to outpace the market, growing at a projected 9.32% CAGR through 2031, making them the fastest-growing segment in the idiopathic short stature market. Ascendis Pharma's SKYTROFA, within just 18 months, secured a notable 6.5% share in the U.S. market. This demonstrates that premium pricing can coexist with payer acceptance, especially when adherence benefits are evident. Conversely, in China, biosimilar approvals reduced therapy costs by 75%, broadening the idiopathic short stature market's accessibility to middle-income families. While Western companies strengthen their market share with connected devices and expanded labels, regional players effectively leverage government tenders to secure volume contracts, particularly in county-level hospitals.

In 2025, children aged 10 and under constituted 65.05% of treated patients. This segment is projected to grow at a robust 9.55% CAGR through 2031, driven by earlier detection of growth deficits through genomic screening. Initiating therapy pre-puberty can secure an annualized growth velocity often surpassing 11 cm. While adolescents still represent a significant portion of the idiopathic short stature market, their growth is tempered due to the diminishing efficacy post growth-plate closure. Health campaigns are now proactively targeting primary schools with height-monitoring initiatives, streamlining referrals to pediatric endocrine clinics.

Geography Analysis

In 2025, North America accounted for 38.13% of global revenue, supported by strong insurance frameworks and high per-capita drug spending. However, only 15% of prior-authorization requests for idiopathic short stature succeed, reflecting ongoing concerns about cost-effectiveness. Despite premium pricing, Skytrofa achieved a 6.5% share in the US market within 18 months, demonstrating physicians' preference for its weekly regimen. Access to treatments in Canada varies by province; some provinces provide reimbursements through exceptional drug programs, while others restrict funding to classical deficiencies, resulting in uneven national uptake.

Asia-Pacific is set to lead with a projected 9.33% CAGR through 2031. In January 2026, China's inclusion in the NRDL reduced patient co-pays by more than half, driving increased demand among urban middle-income families. Genescience dominates the market, holding over 70% of China's rhGH sales and leveraging its scale to deter new entrants. Meanwhile, Indian biosimilar firms are targeting export opportunities in Southeast Asia once the WHO pre-qualification is secured. South Korea and Japan are advancing their domestic pipelines with innovative long-acting analog options.

Europe grapples with the EMA's 2007 decision, leaving many patients reliant on off-label prescriptions. In Germany, funding for idiopathic short stature is tightly regulated, based on criteria such as genetic potential disparity. The UK's NHS rarely approves treatments, typically doing so only on compassionate grounds. Southern European countries rely on regional health authorities, leading to disparities and hindering the market's growth for idiopathic short stature. While Western Europe has adequate cold-chain stability, Eastern Europe continues to face logistical challenges, particularly in rural areas.

1. Anhui Anke Biotechnology (Group) Co., Ltd.
2. Ascendis Pharma
3. BioPartners GmbH
4. Bio-Thera Solutions, Ltd.
5. Eli Lilly and Company
6. Ferring Pharmaceuticals In.
7. F-Hoffmann-La Roche Ltd.
8. GeneScience Pharmaceutical
9. Hanmi Pharmaceutical Co., Ltd.
10. Intas Pharmaceutical
11. Ipsen Pharma Inc.
12. JCR Pharmaceuticals Inc.
13. Kyowa Kirin
14. LG Chem
15. Merck KGaA / EMD Serono
16. Novartis
17. Novo Nordisk
18. Opko Health
19. Pfizer
20. Teva Pharmaceutical Industries

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Prevalence of ISS Diagnosis
  • 4.2.2 Growing Adoption of Rhgh Biosimilars
  • 4.2.3 Expanded Insurance Reimbursement
  • 4.2.4 Long-Acting GH Formulations Pipeline
  • 4.2.5 Genomic Screening for Early Detection
  • 4.2.6 Medical Tourism for Pediatric Endocrinology
• 4.3 Market Restraints
  • 4.3.1 Stringent Regulatory Scrutiny & High Therapy Cost
  • 4.3.2 Low Awareness / Delayed Diagnosis in LICs
  • 4.3.3 Ethical Concerns Over Non-Medical Height Use
  • 4.3.4 Cold-Chain Constraints for Biologics
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Therapy Type
  • 5.1.1 Branded rhGH
  • 5.1.2 Biosimilar rhGH
  • 5.1.3 Long-acting GH analogs
  • 5.1.4 GH secretagogues (oral, pipeline)
• 5.2 By Age Group
  • 5.2.1 Pre-pubertal Children (?10 yrs)
  • 5.2.2 Pubertal Adolescents (11-18 yrs)
• 5.3 By Route of Administration
  • 5.3.1 Daily sub-cutaneous injection
  • 5.3.2 Weekly sub-cutaneous injection
  • 5.3.3 Oral formulations (Pipeline)
• 5.4 By End User
  • 5.4.1 Hospitals
  • 5.4.2 Specialty Endocrine Clinics
  • 5.4.3 Home-care Settings
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market-level Overview, Core Segments, Financials, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
  • 6.3.1 Anhui Anke Biotechnology (Group) Co., Ltd.
  • 6.3.2 Ascendis Pharma
  • 6.3.3 BioPartners GmbH
  • 6.3.4 Bio-Thera Solutions, Ltd.
  • 6.3.5 Eli Lilly and Company
  • 6.3.6 Ferring Pharmaceuticals In.
  • 6.3.7 F-Hoffmann-La Roche Ltd.
  • 6.3.8 GeneScience Pharmaceutical
  • 6.3.9 Hanmi Pharmaceutical Co., Ltd.
  • 6.3.10 Intas Pharmaceuticals Ltd.
  • 6.3.11 Ipsen Pharma Inc.
  • 6.3.12 JCR Pharmaceuticals Inc.
  • 6.3.13 Kyowa Kirin Co., Ltd.
  • 6.3.14 LG Chem Ltd.
  • 6.3.15 Merck KGaA / EMD Serono
  • 6.3.16 Novartis AG
  • 6.3.17 Novo Nordisk A/S
  • 6.3.18 OPKO Health, Inc.
  • 6.3.19 Pfizer Inc.
  • 6.3.20 Teva Pharmaceutical Industries Ltd.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment